$0.0312
-0.086-73.38%
Last update: May 30, 8:00 AM
SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. (SYRS) Stock Price, Quote, News & History
SYRSOTCEM
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.
You can purchase shares of SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. (OTCEM:SYRS) through any online brokerage.
There are no as such competitors for SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc..
SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. has a consensus price target of $3.00.
The stock price for SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. (OTCEM: SYRS) is $0.0312 last updated May 30, 2025 at 8:00 AM EDT.
There are no upcoming dividends for SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc..
SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. does not have any upcoming earnings scheduled.
There is no upcoming split for SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc..
SYROS PHARMACEUTICALS INC by Syros Pharmaceuticals, Inc. is in the Health Care sector and Biotechnology industry. They are listed on the OTCEM.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
